Stifel – so far - is on the hook for more than $166 million in damages, legal fees and settlements in investor complaints ...

Chuck Roberts, who advocated a structured-notes strategy to some clients, has been the subject of 31 customer complaints ...

Some investors recently have seen million dollar plus decisions by FINRA arbitration panels involving complex products ...

Panelists on a FINRA arbitration board cited Randy Anderson's claims of age discrimination when questioning UBS's reasons for ...

Stifel Financial recruited an advisor team that oversaw $2.1 billion in client assets at Oppenheimer & Co., making another big hire for Stifel this year.

"I've always really enjoyed what I do," said Henry, who began doing legal work involving municipal securities in 1981.

FINRA published today the 2025 FINRA Industry Snapshot, the annual statistical report on registered representatives, brokerage firms and market activity that ...

FINRA published today the 2025 FINRA Industry Snapshot, the annual statistical report on registered representatives, brokerage firms and market activity that FINRA oversees.

Investing.com - Stifel raised its price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $123.00 from $94.00 while maintaining a Buy rating on the stock. The company, currently valued at $5.5 ...

In the latest quarter, 4 analysts provided ratings for Stifel Financial SF, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

Stifel expects cloud to account for the company’s entire revenue increase through 2027 and sees total revenue rising about 16% in fiscal 2026 and 20% the following year. Higher spending on data ...